Acadia Healthcare earnings date
Acadia Healthcare (1ACHC) Q3 2026 Earnings Report
IT:1ACHC Q3 2026 EPS Results
- Actual EPS
- EUR 0.54
- Consensus EPS
- EUR 0.41
- Beat/Miss
- Beat by +EUR 0.12
- One Year Ago EPS
- EUR 0.64
IT:1ACHC Q3 2026 Revenue Results
- Actual Revenue
- EUR 801.61M
- Expected Revenue
- EUR 785.90M
- Beat/Miss
- Beat by +EUR 15.71M
- YoY Revenue Growth
- +5.14%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Acadia Healthcare's next earnings date is estimated for March 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive. Acadia reported revenue, adjusted EBITDA, and adjusted EPS above expectations, generated $47 million of free cash flow, reduced debt by $63 million, raised full-year guidance for the third consecutive quarter, opened significant new capacity, and reported strong acute demand and improving CTC admissions. The main challenges were the New York Medicaid headwind, ongoing startup facility losses, flat sequential CTC revenue, lower commercial mix, shorter length of stay, and continued legal and revenue-cycle costs, but management described progress on each operational area and maintained a favorable outlook for 2027.
For 2026, Acadia raised guidance to revenue in a range of $3.44 billion-$3.46 billion, adjusted EBITDA in a range of $615 million-$625 million, adjusted EPS in a range of $1.70-$1.80, and operating cash flow in a range of $375 million-$400 million, while full-year CapEx is forecast in a range of $210 million-$230 million. The company expects approximately $60 million of incremental adjusted EBITDA from facilities opened in 2023, 2024, 2025, and 2026 in 2027 compared to 2026, supporting the previously discussed $200 million of incremental adjusted EBITDA relative to 2025; preliminary math projects startup facility losses declining from about $45 million to around $10 million, with break-even occupancy usually around 40%. Programs in Florida and Ohio could add more than $20 million in incremental EBITDA, but are not included in guidance ranges, and the company expects overall patient day growth to continue to be in that 3%-4% range.
- Revenue and Same-Facility Growth Exceeded ExpectationsThird-quarter revenue was $895 million, up 5.1% year over year. Same-facility revenue increased 5.2%, at the high end of expectations, driven by 1.1% growth in patient days and 4.0% growth in revenue per patient day.
- Adjusted EBITDA and EPS Beat ExpectationsThird-quarter revenue, adjusted EBITDA, and adjusted EPS were above expectations. Consolidated adjusted EBITDA was $176.4 million, while same-facility adjusted EBITDA was $228.8 million, up 6.1% year over year.
- Strong Cash Flow and Debt ReductionOperating cash flow was $98 million and capital expenditures were $51 million, resulting in $47 million of free cash flow. The company repaid $63 million of debt during the quarter, and net leverage was approximately 3.9 times adjusted EBITDA at quarter-end.
- Expanded Acute Facility CapacityAcadia opened Coastal Pines Behavioral Health, a new 144-bed de novo acute facility near Jacksonville, Florida, in August. It was the fourth new acute facility opened in 2026 and the 16th opened since the beginning of 2023.
- Record Pace of Facility Licensing and AccreditationAll facilities included in the development plans are now open. New joint venture facilities, including Orlando Health and Methodist Jennie Edmundson, moved through initial accreditation and licensure at a record pace for Acadia and faster than in prior years.
- Bed Additions and Development ProgressAcadia added 220 licensed beds during the third quarter, including 144 beds at the Jacksonville-area de novo facility and 76 beds at existing facilities. The company has opened 542 beds in 2026, and also opened one new CTC clinic while closing one existing clinic.
- Raised 2026 Financial GuidanceThe company raised full-year 2026 guidance for the third consecutive quarter. Updated guidance calls for revenue of $3.44 billion-$3.46 billion, adjusted EBITDA of $615 million-$625 million, adjusted EPS of $1.70-$1.80, and operating cash flow of $375 million-$400 million.
- Increasing Visibility Into the $200 Million EBITDA OpportunityManagement said positive momentum at facilities opened in 2023, 2024, 2025, and 2026 increased confidence in delivering the previously discussed $200 million of incremental adjusted EBITDA relative to 2025. The company expects approximately $60 million of incremental adjusted EBITDA from these cohorts in 2027 compared with 2026.
- Startup Facility Losses Expected to ImproveManagement expects startup facility losses to decline from approximately $45 million in the current year to around $10 million in 2027. Approximately half of the $60 million incremental EBITDA opportunity is expected to come from startup or newer facilities, with the other half coming from older facilities in the cohort.
- Strong Acute Business PerformanceAcute revenue was $525 million in the third quarter, up 11% year over year. Acute volumes increased 7.5% during the quarter, supported by strong demand and inquiry growth at both legacy and newer joint venture and de novo facilities.
- Positive Specialty and RTC TrendsSpecialty revenue was $136 million and represented positive growth compared with the prior year after normalizing for facility closures and the New York Medicaid impact. RTC revenue was $93 million, up 7% year over year, driven by steady volume growth and higher revenue per day.
- CTC Operational Improvement and Admissions MomentumCTC revenue was $141 million, stable with the second quarter. Demand remained solid, admissions trends improved in September and October following initiatives launched by the company, and management reported increased operational efficiency and a reduced cost structure in the service line.
- Supplemental Payment UpsidePrograms in Florida and Ohio under regulatory review for the 2026 program years could add more than $20 million of incremental EBITDA. These expanded programs were not included in the updated guidance ranges, and management said additional contribution from the 2026 Florida program year may be possible pending final approval.
- Revenue Cycle Stability and Improvement InitiativesBad debts and denials were stable as a percentage of revenue compared with the prior quarter. Management cited steady progress from revenue cycle initiatives, including technology, analytics, improved front-end documentation, faster intervention, and more aggressive appeals.
- Legacy Facility Growth OpportunityLegacy facilities generated 1.6% volume growth during the third quarter. Management said existing facilities continue to have opportunities to increase occupancy, expand services, improve underperforming operations, and grow within existing markets.
- Clinical Quality and Patient Safety ProgressAcadia expanded measurement-based care initiatives across additional acute and specialty facilities, using patient-reported outcomes and other clinical data to guide treatment decisions. Geisinger Behavioral Health Center Northeast received the Joint Commission's inaugural Care Team Award and was recognized as the first recipient of the national honor.
- Leadership and Organizational DevelopmentThe company continued investing in internal talent development, collaboration, and targeted team additions. An executive leadership summit in August strengthened connections among facility CEOs, corporate support teams, and executive leadership.
- Stable Staffing TrendsManagement said labor trends were stable and that Acadia had been able to staff new facilities in a timely manner in almost all markets. The company is using centralized recruiting for positions including CEOs, registered nurses, therapists, and social workers, while also focusing on retention and onboarding.
- Behavioral Healthcare Demand and Policy PositioningManagement continued to see strong demand for behavioral healthcare services and said both political parties recognize the need to protect and expand access to behavioral health and substance use care. Approximately 50% of Medicaid patients are in expansion states, and management does not expect the work requirements under the One Big Beautiful Bill to significantly affect its patients because the vast majority are expected to be exempt.
- New York Referral Replacement ProgressAcadia developed new referral relationships in states surrounding Pennsylvania and saw increased referrals from Pennsylvania after the loss of New York patients. Management said replacement efforts were exceeding expectations, although the process remains ongoing.
- Reduced Capital Expenditure ForecastFollowing a review of ongoing and planned capital projects, Acadia reduced its full-year 2026 capital expenditure forecast to $210 million-$230 million. The company said the largest reductions were related to de novo and joint venture facility investments, while maintenance, IT, and existing-facility investments remained compelling opportunities.
IT:1ACHC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 01, 2027 | 2026 (Q4) | 0.35- | 0.06 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.410.54 | 0.64 | -16.67% (-0.11) | |
| Jul 28, 2026 | 2026 (Q2) | 0.310.34 | 0.74 | -54.22% (-0.40) | |
| Apr 29, 2026 | 2026 (Q1) | 0.240.33 | 0.36 | -7.50% (-0.03) | |
| Feb 25, 2026 | 2025 (Q4) | 0.010.06 | 0.57 | -89.06% (-0.51) | |
| Nov 05, 2025 | 2025 (Q3) | 0.590.64 | 0.81 | -20.88% (-0.17) | |
| Aug 05, 2025 | 2025 (Q2) | 0.620.74 | 0.81 | -8.79% (-0.07) | |
| May 12, 2025 | 2025 (Q1) | 0.320.36 | 0.75 | -52.38% (-0.39) | |
| Feb 27, 2025 | 2024 (Q4) | 0.640.57 | 0.76 | -24.71% (-0.19) | |
| Oct 30, 2024 | 2024 (Q3) | 0.800.81 | 0.81 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


